|
|
|
| Expression of long non-coding RNA LncOC1 and miR-34 in human colorectal cancer and its relationship with the prognosis
|
| SHI Jian1, ZHOU Wubi2 |
| (1. Department of Clinical Laboratory, 2. Department of Pathology, The Affiliated Huai′an No.1 People′ Hospital of Nanjing Medical University, Huai′an Jiangsu 223300, China)
|
|
|
|
|
Abstract Objective: To investigate the expression of long noncoding RNA ovarian cancer associated 1(LncOC1) in colorectal cancer tissues and its correlation with the prognosis of colorectal cancer patients. Methods: The cDNA chip which contains 80 cases of colorectal cancer tissues and 15 cases of paracarcinoma tissues was purchased. The expression of LncOC1 and miR34 were detected by realtime fluorescence quantitative PCR(qRTPCR), and the correlations between LncOC1 and miR34 were analyzed. Results: The expression of LncOC1 in cancer tissues was higher than that in paracarcinoma tissues(t=19.315, P<0.001). LncOC1 expression in colorectal cancer tissues was associated with lymph node metastasis and TNM staging(P＜0.05). LncOC1 expression was negatively correlated with miR34 expression(r=-0.967, P<0.001). The overall survival rate of colorectal cancer patients with high LncOC1 expression was significantly lower than that of patients with low LncOC1 expression(P＜0.001). LncOC1 expression in colorectal cancer was an independent risk factor for prognosis. Conclusion: Colorectal cancer tissues showed higher expression of LncOC1, which suggests poor prognosis of colorectal cancer patients.
|
|
Received: 10 May 2018
|
|
|
|
| ［1］Nagano T,Fraser P. Nononsense functions for long noncoding RNAs\[J\]. Cell,2011, 145(2):178-181.［2］Wang H, Liu Y, Zhong J, et al. Long noncoding RNA ANRIL as a novel biomarker of lymph node metastasis and prognosis in human cancer: a metaanalysis\[J\]. Oncotarget,2018, 9(18):14608-14618.［3］Hu S, Chang J, Li Y, et al. Long noncoding RNA XIST as a potential prognostic biomarker in human cancers: a metaanalysis\[J\]. Oncotarget,2017, 9(17): 13911-13919.［4］Lin HC, Yeh CC, Chao LY, et al. The hypoxiaresponsive lncRNA promotes NDRGOT1 degradation via ubiquitinmediated proteolysis in breast cancer cells\[J\]. Oncotarget, 2018, 9(12):10470-10482.［5］Jeon Y, Sarma K,Lee JT. New and Xisting regulatory mechanisms of X chromosome inactivation\[J\]. Curr Opin Genet Dev, 2012, 22(2):62-71.［6］Liu RH, Wang MY, Chen LY, et al. Metaanalysis of the prognostic value of long noncoding RNA AFAP1AS1 for cancer patients in China\[J\]. Oncotarget, 2017, 9(8): 8100-8110.［7］Tao F, Tian X, Lu M, et al. A novel lncRNA, LncOC1, promotes ovarian cancer cell proliferation and migration by sponging miR34a and miR34c\[J\]. J Genet Genomics, 2018, 45(3):137-145.［8］de Melo Maia B, Ling H, Monroig P, et al. Design of a miRNA sponge for the miR17 miRNA family as a therapeutic strategy against vulvar carcinoma\[J\]. Mol Cell Probes, 2015, 29(6):420-426.［9］Liao W, Zhang H, Feng C, et al. Downregulation of TrkA protein expression by miRNA92a promotes the proliferation and migration of human neuroblastoma cells\[J\]. Mol Med Rep, 2014, 10(2):778-784.［10］Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR34b/c is associated with a reduced risk of colorectal cancer\[J\]. Biol Chem,2013, 394(3): 415-420.［11］Siemens H, Jackstadt R, Kaller M, et al. Repression of cKit by p53 is mediated by miR34 and is associated with reduced chemoresistance, migration and stemness\[J\]. Oncotarget,2013, 4(9):1399-1415.［12］Tomasi ML, Cossu C, Spissu Y, et al. Sadenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/bmethionine adenosyltransferase 2A/2B axis\[J\]. Oncotarget, 2017, 8(45): 78851-78869.［13］Wan Y, Shen A, Qi F, et al. Pien Tze Huang inhibits the proliferation of colorectal cancer cells by increasing the expression of miR34c5p\[J\]. Exp Ther Med, 2017, 14(4): 3901-3907.［14］Liu G, Jiang C, Li D, et al. MiRNA34a inhibits EGFRsignalingdependent MMP7 activation in gastric cancer\[J\]. Tumour Biol,2014, 35(10):9801-9806.［15］Kasinski AL,Slack FJ. miRNA34 prevents cancer initiation and progression in a therapeutically resistant Kras and p53induced mouse model of lung adenocarcinoma\[J\]. Cancer Res, 2012, 72(21):5576-5587.［16］Hashemi M, Bahari G, Naderi M, et al. PrimiR34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia\[J\]. Cancer Genet, 2016, 209(11):493-496.［17］Zhang QA, Yang XH, Chen D, et al. miR34 increases in vitro PANC1 cell sensitivity to gemcitabine via targeting Slug/PUMA\[J\]. Cancer Biomark,2018, 21(4): 755-762.［18］Hermeking H. The miR34 family in cancer and apoptosis\[J\]. Cell Death Differ, 2010, 17(2):193-199. |
|
|
|
2018, Vol. 28 
